25 XP   0   0   10

Regenxbio Inc
Buy, Hold or Sell?

Let's analyse Regenxbio together

PenkeI guess you are interested in Regenxbio Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Regenxbio Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Regenxbio Inc

I send you an email if I find something interesting about Regenxbio Inc.

Quick analysis of Regenxbio (30 sec.)










What can you expect buying and holding a share of Regenxbio? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.36
Expected worth in 1 year
$-10.33
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-16.69
Return On Investment
-100.3%

For what price can you sell your share?

Current Price per Share
$16.64
Expected price per share
$11.83 - $26.03
How sure are you?
50%

1. Valuation of Regenxbio (5 min.)




Live pricePrice per Share (EOD)

$16.64

Intrinsic Value Per Share

$-64.86 - $-30.87

Total Value Per Share

$-58.50 - $-24.50

2. Growth of Regenxbio (5 min.)




Is Regenxbio growing?

Current yearPrevious yearGrowGrow %
How rich?$311.7m$516.1m-$204.4m-65.6%

How much money is Regenxbio making?

Current yearPrevious yearGrowGrow %
Making money-$263.4m-$280.3m$16.8m6.4%
Net Profit Margin-292.0%-248.7%--

How much money comes from the company's main activities?

3. Financial Health of Regenxbio (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#173 / 1007

Most Revenue
#213 / 1007

Most Profit
#924 / 1007

Most Efficient
#673 / 1007

What can you expect buying and holding a share of Regenxbio? (5 min.)

Welcome investor! Regenxbio's management wants to use your money to grow the business. In return you get a share of Regenxbio.

What can you expect buying and holding a share of Regenxbio?

First you should know what it really means to hold a share of Regenxbio. And how you can make/lose money.

Speculation

The Price per Share of Regenxbio is $16.64. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Regenxbio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Regenxbio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.36. Based on the TTM, the Book Value Change Per Share is $-4.17 per quarter. Based on the YOY, the Book Value Change Per Share is $-5.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Regenxbio.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-5.38-32.3%-5.38-32.3%-5.72-34.4%-2.54-15.3%-1.40-8.4%
Usd Book Value Change Per Share-4.17-25.1%-4.17-25.1%-5.06-30.4%-0.80-4.8%0.643.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-4.17-25.1%-4.17-25.1%-5.06-30.4%-0.80-4.8%0.643.9%
Usd Price Per Share17.95-17.95-22.68-31.93-27.00-
Price to Earnings Ratio-3.34--3.34--3.96--7.19--8.62-
Price-to-Total Gains Ratio-4.30--4.30--4.48--13.91-0.05-
Price to Book Ratio2.82-2.82-2.15-3.48-3.97-
Price-to-Total Gains Ratio-4.30--4.30--4.48--13.91-0.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share16.64
Number of shares60
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-4.17-0.80
Usd Total Gains Per Share-4.17-0.80
Gains per Quarter (60 shares)-250.39-48.28
Gains per Year (60 shares)-1,001.55-193.11
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1002-10120-193-203
20-2003-20140-386-396
30-3005-30160-579-589
40-4006-40180-772-782
50-5008-50200-966-975
60-6009-60220-1159-1168
70-7011-70240-1352-1361
80-8012-80260-1545-1554
90-9014-90280-1738-1747
100-10015-100300-1931-1940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%2.08.00.020.0%2.09.00.018.2%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%4.07.00.036.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.011.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%4.07.00.036.4%

Fundamentals of Regenxbio

About Regenxbio Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-04-12 16:37:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Regenxbio Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Regenxbio earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • A Net Profit Margin of -292.0% means that $-2.92 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Regenxbio Inc:

  • The MRQ is -292.0%. The company is making a huge loss. -2
  • The TTM is -292.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-292.0%TTM-292.0%0.0%
TTM-292.0%YOY-248.7%-43.3%
TTM-292.0%5Y-170.9%-121.1%
5Y-170.9%10Y-325.1%+154.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-292.0%-207.2%-84.8%
TTM-292.0%-218.5%-73.5%
YOY-248.7%-282.4%+33.7%
5Y-170.9%-432.2%+261.3%
10Y-325.1%-593.8%+268.7%
1.1.2. Return on Assets

Shows how efficient Regenxbio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • -45.9% Return on Assets means that Regenxbio generated $-0.46 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Regenxbio Inc:

  • The MRQ is -45.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -45.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-45.9%TTM-45.9%0.0%
TTM-45.9%YOY-33.6%-12.3%
TTM-45.9%5Y-20.6%-25.3%
5Y-20.6%10Y-28.3%+7.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-45.9%-13.2%-32.7%
TTM-45.9%-12.6%-33.3%
YOY-33.6%-11.5%-22.1%
5Y-20.6%-13.7%-6.9%
10Y-28.3%-15.5%-12.8%
1.1.3. Return on Equity

Shows how efficient Regenxbio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • -84.5% Return on Equity means Regenxbio generated $-0.85 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Regenxbio Inc:

  • The MRQ is -84.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -84.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-84.5%TTM-84.5%0.0%
TTM-84.5%YOY-54.3%-30.2%
TTM-84.5%5Y-34.5%-50.0%
5Y-34.5%10Y-24.2%-10.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-84.5%-16.7%-67.8%
TTM-84.5%-15.8%-68.7%
YOY-54.3%-14.4%-39.9%
5Y-34.5%-19.0%-15.5%
10Y-24.2%-19.9%-4.3%

1.2. Operating Efficiency of Regenxbio Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Regenxbio is operating .

  • Measures how much profit Regenxbio makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • An Operating Margin of -297.1% means the company generated $-2.97  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Regenxbio Inc:

  • The MRQ is -297.1%. The company is operating very inefficient. -2
  • The TTM is -297.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-297.1%TTM-297.1%0.0%
TTM-297.1%YOY-233.2%-63.9%
TTM-297.1%5Y-199.3%-97.9%
5Y-199.3%10Y-353.2%+154.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-297.1%-286.5%-10.6%
TTM-297.1%-229.1%-68.0%
YOY-233.2%-288.4%+55.2%
5Y-199.3%-480.7%+281.4%
10Y-353.2%-624.7%+271.5%
1.2.2. Operating Ratio

Measures how efficient Regenxbio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.97 means that the operating costs are $3.97 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Regenxbio Inc:

  • The MRQ is 3.971. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.971. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.971TTM3.9710.000
TTM3.971YOY3.332+0.639
TTM3.9715Y2.993+0.979
5Y2.99310Y4.474-1.481
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9713.231+0.740
TTM3.9713.307+0.664
YOY3.3323.774-0.442
5Y2.9935.667-2.674
10Y4.4747.558-3.084

1.3. Liquidity of Regenxbio Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Regenxbio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.57 means the company has $2.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Regenxbio Inc:

  • The MRQ is 2.571. The company is able to pay all its short-term debts. +1
  • The TTM is 2.571. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.571TTM2.5710.000
TTM2.571YOY3.189-0.618
TTM2.5715Y5.301-2.730
5Y5.30110Y9.059-3.759
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5713.890-1.319
TTM2.5714.182-1.611
YOY3.1895.343-2.154
5Y5.3016.135-0.834
10Y9.0596.453+2.606
1.3.2. Quick Ratio

Measures if Regenxbio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • A Quick Ratio of 4.16 means the company can pay off $4.16 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Regenxbio Inc:

  • The MRQ is 4.163. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.163. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.163TTM4.1630.000
TTM4.163YOY5.063-0.900
TTM4.1635Y7.711-3.548
5Y7.71110Y14.700-6.989
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1633.528+0.635
TTM4.1634.059+0.104
YOY5.0635.390-0.327
5Y7.7116.138+1.573
10Y14.7006.488+8.212

1.4. Solvency of Regenxbio Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Regenxbio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Regenxbio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.46 means that Regenxbio assets are financed with 45.7% credit (debt) and the remaining percentage (100% - 45.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Regenxbio Inc:

  • The MRQ is 0.457. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.457. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.457TTM0.4570.000
TTM0.457YOY0.381+0.076
TTM0.4575Y0.343+0.114
5Y0.34310Y0.457-0.115
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4570.339+0.118
TTM0.4570.337+0.120
YOY0.3810.273+0.108
5Y0.3430.368-0.025
10Y0.4570.391+0.066
1.4.2. Debt to Equity Ratio

Measures if Regenxbio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • A Debt to Equity ratio of 84.1% means that company has $0.84 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Regenxbio Inc:

  • The MRQ is 0.841. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.841. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.841TTM0.8410.000
TTM0.841YOY0.614+0.227
TTM0.8415Y0.579+0.262
5Y0.57910Y0.314+0.265
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8410.388+0.453
TTM0.8410.403+0.438
YOY0.6140.342+0.272
5Y0.5790.432+0.147
10Y0.3140.461-0.147

2. Market Valuation of Regenxbio Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Regenxbio generates.

  • Above 15 is considered overpriced but always compare Regenxbio to the Biotechnology industry mean.
  • A PE ratio of -3.34 means the investor is paying $-3.34 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Regenxbio Inc:

  • The EOD is -3.094. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.338. Based on the earnings, the company is expensive. -2
  • The TTM is -3.338. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.094MRQ-3.338+0.244
MRQ-3.338TTM-3.3380.000
TTM-3.338YOY-3.964+0.626
TTM-3.3385Y-7.187+3.849
5Y-7.18710Y-8.624+1.437
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.094-2.249-0.845
MRQ-3.338-2.553-0.785
TTM-3.338-2.669-0.669
YOY-3.964-4.107+0.143
5Y-7.187-6.247-0.940
10Y-8.624-6.499-2.125
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Regenxbio Inc:

  • The EOD is -3.570. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.851. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.851. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.570MRQ-3.851+0.281
MRQ-3.851TTM-3.8510.000
TTM-3.851YOY-4.665+0.814
TTM-3.8515Y-8.178+4.327
5Y-8.17810Y-9.473+1.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.570-2.858-0.712
MRQ-3.851-3.288-0.563
TTM-3.851-3.552-0.299
YOY-4.665-5.560+0.895
5Y-8.178-8.326+0.148
10Y-9.473-8.881-0.592
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Regenxbio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.82 means the investor is paying $2.82 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Regenxbio Inc:

  • The EOD is 2.615. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.821. Based on the equity, the company is underpriced. +1
  • The TTM is 2.821. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.615MRQ2.821-0.206
MRQ2.821TTM2.8210.000
TTM2.821YOY2.153+0.668
TTM2.8215Y3.482-0.661
5Y3.48210Y3.972-0.490
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6151.929+0.686
MRQ2.8212.090+0.731
TTM2.8212.091+0.730
YOY2.1532.881-0.728
5Y3.4823.545-0.063
10Y3.9723.936+0.036
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Regenxbio Inc.

3.1. Institutions holding Regenxbio Inc

Institutions are holding 82.62% of the shares of Regenxbio Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc18.4740.003882075481810582.2558
2023-12-31Vanguard Group Inc9.99570.00174440838642651.4684
2023-12-31JPMorgan Chase & Co8.86740.006839395492741857.4804
2023-12-31State Street Corporation5.92250.002326312201277395.1025
2023-09-30Redmile Group, LLC5.79382.0159257404254746627.0143
2023-12-31Morgan Stanley - Brokerage Accounts4.09740.002918203821438467376.6459
2023-12-31Dimensional Fund Advisors, Inc.2.76170.00641226957343852.8833
2023-12-31Geode Capital Management, LLC2.09260.0018929672465265.2682
2023-12-31Aquilo Capital Management, LLC1.80618.9768802424-45000-5.3102
2023-09-30Citadel Advisors Llc1.62320.00257211617076510.8803
2023-12-31Goldman Sachs Group Inc1.51310.00116722127535812.6259
2023-09-30Jacobs Levy Equity Management, Inc.1.26590.054856239114930.2662
2023-12-31MPM Oncology Impact Management LP1.23592.3059549078-107640-16.3906
2023-12-31Northern Trust Corp1.00560.0015446773167383.8922
2023-12-31Sonic GP LLC0.99739.1358443079-75000-14.4766
2023-12-31WS Management LLP0.97060.4595431200-186931-30.2413
2023-12-31Ameriprise Financial Inc0.8480.00237672811706045.0806
2023-12-31Perceptive Advisors LLC0.77070.13723424083424080
2023-12-31Bank of New York Mellon Corp0.76030.0012337773-22923-6.3552
2023-12-31Charles Schwab Investment Management Inc0.7370.001532745116830.5166
Total 71.538823.121431782886+2902102+9.1%

3.2. Funds holding Regenxbio Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Core S&P Small-Cap ETF6.21960.0622276322744460.1612
2024-01-31JPMorgan Small Cap Growth A2.89430.43931285847-37591-2.8404
2024-02-29Vanguard Total Stock Mkt Idx Inv2.78930.0014123923700
2024-02-29SPDR® S&P Biotech ETF2.55640.25011135738212401.9058
2024-02-29JPM Global Healthcare C (acc) USD2.39690.44341064900-19077-1.7599
2024-02-29Vanguard Small Cap Index2.29670.0127102037593460.9244
2024-02-29iShares Russell 2000 ETF2.23610.0278993450-162-0.0163
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.33490.01015930574760.0803
2024-02-29Vanguard Small Cap Growth Index Inv1.28930.028657279895231.6906
2024-02-29JPM Thematics Genetic Thrps C2 Acc USD0.99721.0781443019-6703-1.4905
2023-12-31Fidelity Small Cap Index0.91970.028940859495832.4017
2024-02-01iShares Russell 2000 Value ETF0.86520.04133843844860.1266
2024-02-29SPDR® Portfolio S&P 600 Sm Cap ETF0.83320.0629370183750.0203
2024-02-29BlackRock Advantage Small Cap Core Instl0.77350.1708343643-30722-8.2064
2024-02-29Vanguard Tax-Managed Small Cap Adm0.71170.062131620200
2024-02-29iShares Biotechnology ETF0.69160.0705307277-1385-0.4487
2024-02-29iShares S&P Small-Cap 600 Value ETF0.65430.07212907037980.2753
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.55440.010324630236001.4833
2024-01-31JPMorgan Small Cap Blend A0.55410.2215246161-2051-0.8263
2024-01-31Fidelity Extended Market Index0.50850.007822592024341.0891
Total 32.07693.101914251017-35684-0.3%

3.3. Insider Transactions

Insiders are holding 7.426% of the shares of Regenxbio Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-14Kenneth T MillsSELL1500021.86
2024-03-05Steve PakolaSELL1287828.36
2024-02-14Kenneth T MillsSELL1500016.76
2024-01-16Kenneth T MillsSELL4500015.18
2024-01-03Steve PakolaSELL1723717.39
2023-12-19Kenneth T MillsSELL4500019.68

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Regenxbio Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---4.173-4.1730%-5.064+21%-0.805-81%0.641-751%
Book Value Per Share--6.3636.3630%10.536-40%9.880-36%7.113-11%
Current Ratio--2.5712.5710%3.189-19%5.301-51%9.059-72%
Debt To Asset Ratio--0.4570.4570%0.381+20%0.343+33%0.4570%
Debt To Equity Ratio--0.8410.8410%0.614+37%0.579+45%0.314+168%
Dividend Per Share----0%-0%-0%-0%
Eps---5.378-5.3780%-5.722+6%-2.539-53%-1.402-74%
Free Cash Flow Per Share---4.661-4.6610%-4.862+4%-2.173-53%-1.201-74%
Free Cash Flow To Equity Per Share---5.375-5.3750%-5.451+1%-0.785-85%0.577-1031%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---30.865--------
Intrinsic Value_10Y_min---64.864--------
Intrinsic Value_1Y_max---1.612--------
Intrinsic Value_1Y_min---3.362--------
Intrinsic Value_3Y_max---5.972--------
Intrinsic Value_3Y_min---12.878--------
Intrinsic Value_5Y_max---11.693--------
Intrinsic Value_5Y_min---25.366--------
Market Cap815240192.000-8%879420760.000879420760.0000%1111156704.000-21%1564438089.600-44%1322854592.800-34%
Net Profit Margin---2.920-2.9200%-2.487-15%-1.709-41%-3.251+11%
Operating Margin---2.971-2.9710%-2.332-22%-1.993-33%-3.532+19%
Operating Ratio--3.9713.9710%3.332+19%2.993+33%4.474-11%
Pb Ratio2.615-8%2.8212.8210%2.153+31%3.482-19%3.972-29%
Pe Ratio-3.094+7%-3.338-3.3380%-3.964+19%-7.187+115%-8.624+158%
Price Per Share16.640-8%17.95017.9500%22.680-21%31.932-44%27.001-34%
Price To Free Cash Flow Ratio-3.570+7%-3.851-3.8510%-4.665+21%-8.178+112%-9.473+146%
Price To Total Gains Ratio-3.987+7%-4.301-4.3010%-4.479+4%-13.907+223%0.048-9031%
Quick Ratio--4.1634.1630%5.063-18%7.711-46%14.700-72%
Return On Assets---0.459-0.4590%-0.336-27%-0.206-55%-0.283-38%
Return On Equity---0.845-0.8450%-0.543-36%-0.345-59%-0.242-71%
Total Gains Per Share---4.173-4.1730%-5.064+21%-0.805-81%0.641-751%
Usd Book Value--311742000.000311742000.0000%516195000.000-40%484037000.000-36%348490900.000-11%
Usd Book Value Change Per Share---4.173-4.1730%-5.064+21%-0.805-81%0.641-751%
Usd Book Value Per Share--6.3636.3630%10.536-40%9.880-36%7.113-11%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---5.378-5.3780%-5.722+6%-2.539-53%-1.402-74%
Usd Free Cash Flow---228367000.000-228367000.0000%-238212000.000+4%-106446800.000-53%-58815900.000-74%
Usd Free Cash Flow Per Share---4.661-4.6610%-4.862+4%-2.173-53%-1.201-74%
Usd Free Cash Flow To Equity Per Share---5.375-5.3750%-5.451+1%-0.785-85%0.577-1031%
Usd Market Cap815240192.000-8%879420760.000879420760.0000%1111156704.000-21%1564438089.600-44%1322854592.800-34%
Usd Price Per Share16.640-8%17.95017.9500%22.680-21%31.932-44%27.001-34%
Usd Profit---263494000.000-263494000.0000%-280321000.000+6%-124391600.000-53%-68497100.000-74%
Usd Revenue--90242000.00090242000.0000%112724000.000-20%172622600.000-48%111030800.000-19%
Usd Total Gains Per Share---4.173-4.1730%-5.064+21%-0.805-81%0.641-751%
 EOD+3 -5MRQTTM+0 -0YOY+14 -195Y+3 -3010Y+6 -27

4.2. Fundamental Score

Let's check the fundamental score of Regenxbio Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.094
Price to Book Ratio (EOD)Between0-12.615
Net Profit Margin (MRQ)Greater than0-2.920
Operating Margin (MRQ)Greater than0-2.971
Quick Ratio (MRQ)Greater than14.163
Current Ratio (MRQ)Greater than12.571
Debt to Asset Ratio (MRQ)Less than10.457
Debt to Equity Ratio (MRQ)Less than10.841
Return on Equity (MRQ)Greater than0.15-0.845
Return on Assets (MRQ)Greater than0.05-0.459
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Regenxbio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.437
Ma 20Greater thanMa 5017.088
Ma 50Greater thanMa 10019.615
Ma 100Greater thanMa 20017.961
OpenGreater thanClose16.330
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Net Debt  -58,219-207,554-265,7737,245-258,528256,375-2,15356,92154,768



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets573,970
Total Liabilities262,228
Total Stockholder Equity311,742
 As reported
Total Liabilities 262,228
Total Stockholder Equity+ 311,742
Total Assets = 573,970

Assets

Total Assets573,970
Total Current Assets334,971
Long-term Assets238,999
Total Current Assets
Cash And Cash Equivalents 34,522
Short-term Investments 240,736
Net Receivables 26,341
Other Current Assets 33,372
Total Current Assets  (as reported)334,971
Total Current Assets  (calculated)334,971
+/-0
Long-term Assets
Property Plant Equipment 192,590
Long Term Investments 38,871
Long-term Assets Other 4,807
Long-term Assets  (as reported)238,999
Long-term Assets  (calculated)236,268
+/- 2,731

Liabilities & Shareholders' Equity

Total Current Liabilities130,272
Long-term Liabilities131,956
Total Stockholder Equity311,742
Total Current Liabilities
Short-term Debt 7,068
Accounts payable 22,786
Other Current Liabilities 100,270
Total Current Liabilities  (as reported)130,272
Total Current Liabilities  (calculated)130,124
+/- 148
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt82,222
Long-term Liabilities Other 49,734
Long-term Liabilities  (as reported)131,956
Long-term Liabilities  (calculated)131,956
+/-0
Total Stockholder Equity
Common Stock4
Retained Earnings -705,047
Accumulated Other Comprehensive Income -4,429
Other Stockholders Equity 1,021,214
Total Stockholder Equity (as reported)311,742
Total Stockholder Equity (calculated)311,742
+/-0
Other
Capital Stock4
Cash and Short Term Investments 275,258
Common Stock Shares Outstanding 43,734
Current Deferred Revenue148
Liabilities and Stockholders Equity 573,970
Net Debt 54,768
Net Invested Capital 311,742
Net Working Capital 204,699
Property Plant and Equipment Gross 249,798
Short Long Term Debt Total 89,290



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
> Total Assets 
2,510
3,491
221,380
172,732
198,677
543,814
497,908
708,164
1,113,904
833,268
573,970
573,970833,2681,113,904708,164497,908543,814198,677172,732221,3803,4912,510
   > Total Current Assets 
2,207
3,031
118,148
93,371
167,997
337,913
345,032
531,197
518,826
415,976
334,971
334,971415,976518,826531,197345,032337,913167,99793,371118,1483,0312,207
       Cash And Cash Equivalents 
1,119
1,121
54,116
24,840
46,656
75,561
69,514
338,426
345,209
96,952
34,522
34,52296,952345,209338,42669,51475,56146,65624,84054,1161,1211,119
       Short-term Investments 
0
60,025
60,025
64,714
114,122
244,200
226,696
137,314
112,230
267,690
240,736
240,736267,690112,230137,314226,696244,200114,12264,71460,02560,0250
       Net Receivables 
1,088
1,882
2,136
1,032
473
8,587
38,148
42,999
32,439
28,082
26,341
26,34128,08232,43942,99938,1488,5874731,0322,1361,8821,088
       Other Current Assets 
0
28
851
1,010
1,412
3,831
4,199
1,953
10,196
9,352
33,372
33,3729,35210,1961,9534,1993,8311,4121,010851280
   > Long-term Assets 
303
460
103,232
79,361
30,680
205,901
152,876
176,967
595,078
417,292
238,999
238,999417,292595,078176,967152,876205,90130,68079,361103,232460303
       Property Plant Equipment 
0
538
538
9,324
13,977
28,702
39,051
120,282
192,451
206,801
192,590
192,590206,801192,451120,28239,05128,70213,9779,3245385380
       Long Term Investments 
0
303
102,526
69,412
15,616
150,819
103,785
50,076
394,169
200,560
38,871
38,871200,560394,16950,076103,785150,81915,61669,412102,5263030
       Other Assets 
0
157
168
625
687
25,980
10,040
8,776
1,113,904
9,931
0
09,9311,113,9048,77610,04025,9806876251681570
> Total Liabilities 
4,653
9,189
4,572
10,995
15,648
34,966
47,711
330,411
349,606
317,073
262,228
262,228317,073349,606330,41147,71134,96615,64810,9954,5729,1894,653
   > Total Current Liabilities 
4,653
9,189
4,339
9,669
14,437
22,176
33,676
81,447
130,472
130,434
130,272
130,272130,434130,47281,44733,67622,17614,4379,6694,3399,1894,653
       Short-term Debt 
0
2,403
0
0
0
0
2,421
2,500
1,752
5,997
7,068
7,0685,9971,7522,5002,42100002,4030
       Short Long Term Debt 
0
3,826
0
0
0
0
0
0
0
0
0
0000000003,8260
       Accounts payable 
301
334
1,014
1,543
4,832
4,412
6,409
10,622
11,387
27,213
22,786
22,78627,21311,38710,6226,4094,4124,8321,5431,014334301
       Other Current Liabilities 
4,352
12,598
3,198
8,126
9,605
17,164
21,513
67,876
114,000
95,395
100,270
100,27095,395114,00067,87621,51317,1649,6058,1263,19812,5984,352
   > Long-term Liabilities 
0
0
233
1,326
1,211
12,790
14,035
248,964
219,134
186,639
131,956
131,956186,639219,134248,96414,03512,7901,2111,32623300
       Long term Debt Total 
0
0
0
0
0
5,854
0
0
0
0
0
000005,85400000
       Other Liabilities 
0
0
233
1,326
1,211
6,936
5,161
178,811
134,205
97,837
0
097,837134,205178,8115,1616,9361,2111,32623300
       Deferred Long Term Liability 
0
157
0
1,326
1,211
1,098
0
0
0
0
0
000001,0981,2111,32601570
> Total Stockholder Equity
-2,143
-5,698
216,808
161,737
183,029
508,848
450,197
377,753
764,298
516,195
311,742
311,742516,195764,298377,753450,197508,848183,029161,737216,808-5,698-2,143
   Common Stock
10,885
3
3
3
3
4
4
4
4
4
4
444444333310,885
   Retained Earnings -705,047-441,553-161,232-289,072-177,822-83,016-187,756-114,587-51,620-28,809-24,806
   Capital Surplus 
0
0
269,144
276,354
371,497
592,580
627,810
667,181
928,095
0
0
00928,095667,181627,810592,580371,497276,354269,14400
   Treasury Stock00000000000
   Other Stockholders Equity 
0
10,518
269,144
276,354
371,497
592,580
627,810
667,181
928,095
973,145
1,021,214
1,021,214973,145928,095667,181627,810592,580371,497276,354269,14410,5180



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue90,242
Cost of Revenue-54,533
Gross Profit35,70935,709
 
Operating Income (+$)
Gross Profit35,709
Operating Expense-303,837
Operating Income-268,128-268,128
 
Operating Expense (+$)
Research Development214,946
Selling General Administrative88,494
Selling And Marketing Expenses0
Operating Expense303,837303,440
 
Net Interest Income (+$)
Interest Income243
Interest Expense-6,862
Other Finance Cost-2,947
Net Interest Income-9,566
 
Pretax Income (+$)
Operating Income-268,128
Net Interest Income-9,566
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-263,646-272,610
EBIT - interestExpense = -274,990
-263,646
-256,632
Interest Expense6,862
Earnings Before Interest and Taxes (EBIT)-268,128-256,784
Earnings Before Interest and Taxes (EBITDA)-250,808
 
After tax Income (+$)
Income Before Tax-263,646
Tax Provision--43
Net Income From Continuing Ops-260,540-263,603
Net Income-263,494
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses358,370
Total Other Income/Expenses Net4,4829,566
 

Technical Analysis of Regenxbio
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Regenxbio. The general trend of Regenxbio is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Regenxbio's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Regenxbio Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 17.12 < 23.14 < 26.03.

The bearish price targets are: 15.18 > 11.83.

Tweet this
Regenxbio Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Regenxbio Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Regenxbio Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Regenxbio Inc. The current macd is -1.04466665.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Regenxbio price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Regenxbio. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Regenxbio price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Regenxbio Inc Daily Moving Average Convergence/Divergence (MACD) ChartRegenxbio Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Regenxbio Inc. The current adx is 31.46.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Regenxbio shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Regenxbio Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Regenxbio Inc. The current sar is 15.27.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Regenxbio Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Regenxbio Inc. The current rsi is 41.44. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Regenxbio Inc Daily Relative Strength Index (RSI) ChartRegenxbio Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Regenxbio Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Regenxbio price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Regenxbio Inc Daily Stochastic Oscillator ChartRegenxbio Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Regenxbio Inc. The current cci is -35.2969085.

Regenxbio Inc Daily Commodity Channel Index (CCI) ChartRegenxbio Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Regenxbio Inc. The current cmo is -8.27603278.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Regenxbio Inc Daily Chande Momentum Oscillator (CMO) ChartRegenxbio Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Regenxbio Inc. The current willr is -57.92507205.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Regenxbio is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Regenxbio Inc Daily Williams %R ChartRegenxbio Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Regenxbio Inc.

Regenxbio Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Regenxbio Inc. The current atr is 1.06539559.

Regenxbio Inc Daily Average True Range (ATR) ChartRegenxbio Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Regenxbio Inc. The current obv is 8,870,156.

Regenxbio Inc Daily On-Balance Volume (OBV) ChartRegenxbio Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Regenxbio Inc. The current mfi is 38.22.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Regenxbio Inc Daily Money Flow Index (MFI) ChartRegenxbio Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Regenxbio Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Regenxbio Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Regenxbio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.437
Ma 20Greater thanMa 5017.088
Ma 50Greater thanMa 10019.615
Ma 100Greater thanMa 20017.961
OpenGreater thanClose16.330
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Regenxbio with someone you think should read this too:
  • Are you bullish or bearish on Regenxbio? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Regenxbio? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Regenxbio Inc

I send you an email if I find something interesting about Regenxbio Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Regenxbio Inc.

Receive notifications about Regenxbio Inc in your mailbox!